/ETNB
ETNB Stock - 89bio, Inc.
Healthcare|BiotechnologyNASDAQ
$14.84+0.00%
+$0.00 (+0.00%) • Oct 30
65
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).45
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.69
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-2.3%upside
Target: $14.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ETNB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$14.69 – $14.99
TARGET (TP)$14.50
STOP LOSS$13.65
RISK/REWARD1:-0.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.26
52W High$15.06
52W Low$4.16
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-38,000 | $-273,000 | $-240,000 | $-79,000 | $-60,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-384,656,000 | $-151,204,000 | $102.25M | $-89,743,000 | $-49,355,000 |
| Net Income | $-367,079,000 | $-142,189,000 | $-102,026,000 | $-90,122,000 | $-49,499,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.51 | $-2.00 | $-2.93 | $-4.48 | $-3.08 |
Company Overview
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
1
13%
Buy / Outperform
6
75%
Hold / Neutral
1
13%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
7 Bullish1 Neutral/Bearish
Price Targets
$26
Average Target
↑ 76.9% Upside
Now
$11
Low
$26
Average
$49
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 4th 2025 | H.C. Wainwright | Resumed | Buy | $32 |
| March 14th 2025 | Goldman | Initiation | Neutral | $11 |
| March 13th 2025 | Citigroup | Initiation | Buy | $25 |
| February 4th 2025 | Wolfe Research | Initiation | Outperform | - |
| April 22nd 2024 | BofA Securities | Resumed | Buy | $30 |
| January 12th 2024 | RBC Capital Mkts | Downgrade | Sector Perform | $15← $24 |
| October 10th 2023 | Oppenheimer | Downgrade | Perform | - |
| August 28th 2023 | UBS | Initiation | Buy | $36 |
| June 13th 2023 | Evercore ISI | Initiation | Outperform | $49 |
| May 12th 2022 | Raymond James | Upgrade | Strong Buy | $12← $33 |
Earnings History & Surprises
ETNBBeat Rate
45%
Last 20 quarters
Avg Surprise
-20.5%
EPS vs Estimate
Beats / Misses
9/11
Last 12 quarters
Latest EPS
$-1.39
Q4 2025
EPS Surprise History
Q1 24
-2.0%
$-0.50vs$-0.49
Q2 24
-17.4%
$-0.54vs$-0.46
Q3 24
+15.8%
$-0.48vs$-0.57
Q4 24
-117.2%
$-1.39vs$-0.64
Q1 25
-70.0%
$-1.02vs$-0.60
Q2 25
+2.0%
$-0.49vs$-0.50
Q3 25
-44.9%
$-0.71vs$-0.49
Q4 25
-178.0%
$-1.39vs$-0.50
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 6, 2025 | $-0.50 | $-1.39 | -178.0% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.49 | $-0.71 | -44.9% | ✗ MISS |
Q2 2025 | May 1, 2025 | $-0.50 | $-0.49 | +2.0% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.60 | $-1.02 | -70.0% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.64 | $-1.39 | -117.2% | ✗ MISS |
Q3 2024 | Aug 5, 2024 | $-0.57 | $-0.48 | +15.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.46 | $-0.54 | -17.4% | ✗ MISS |
Q1 2024 | Feb 29, 2024 | $-0.49 | $-0.50 | -2.0% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.53 | $-0.45 | +15.1% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.41 | $-0.52 | -26.8% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.56 | $-0.54 | +3.6% | ✓ BEAT |
Q1 2023 | Mar 10, 2023 | $-0.69 | $-0.48 | +30.4% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.80 | $-0.57 | +28.8% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-1.05 | $-1.23 | -17.1% | ✗ MISS |
Q2 2022 | May 11, 2022 | $-1.29 | $-1.26 | +2.3% | ✓ BEAT |
Q1 2022 | Mar 24, 2022 | $-1.31 | $-1.30 | +0.8% | ✓ BEAT |
Q4 2021 | Nov 11, 2021 | $-1.06 | $-1.41 | -33.0% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.84 | $-1.03 | -22.6% | ✗ MISS |
Q2 2021 | May 12, 2021 | $-0.69 | $-0.74 | -7.2% | ✗ MISS |
Q1 2021 | Mar 24, 2021 | $-0.87 | $-0.63 | +27.6% | ✓ BEAT |
Latest News
Cantor Fitzgerald Suspends Overweight Rating on 89bio
📉 NegativeBenzinga•Oct 31, 2025, 01:47 PM
Roche Completes Tender Offer For 89bio, Accepts All Validly Tendered Shares At $14.50 Per Share Plus Up To $6.00 In Contingent Payments
📈 PositiveBenzinga•Oct 30, 2025, 06:05 AM•Also:
Roche Launches Tender Offer To Acquire 89bio For $14.50/Share, Plus A Non-Tradeable Contingent Value Right To Receive Certain Milestone Payments Of Up To An Aggregate Of $6.00 Per Share In Cash; Tender Offer Is Being Made Pursuant To The Previously Announced Merger Agreement Dated As Of September 17, 2025
📈 PositiveBenzinga•Oct 1, 2025, 08:34 PM•Also:
Raymond James Downgrades 89bio to Market Perform
📉 NegativeBenzinga•Sep 19, 2025, 05:25 PM
Wolfe Research Downgrades 89bio to Peer Perform
📉 NegativeBenzinga•Sep 19, 2025, 11:53 AM
HC Wainwright & Co. Downgrades 89bio to Neutral, Announces $14.5 Price Target
➖ NeutralBenzinga•Sep 19, 2025, 11:23 AM
Roche deal to buy 89bio boosts MASH space
📈 PositiveSeeking Alpha•Sep 18, 2025, 02:41 PM•Also:
89bio shares are trading higher after the company announced an agreement to be acquired by Roche.
📈 PositiveBenzinga•Sep 18, 2025, 01:18 PM•Also:
Roche To Acquire 89bio In $3.5B Deal Enhancing Pipeline In Cardiovascular, Renal, And Metabolic Diseases With FGF21 Analog
📈 PositiveBenzinga•Sep 18, 2025, 06:42 AM•Also:
HC Wainwright & Co. Assumes 89bio at Buy, Announces Price Target of $32
📈 PositiveBenzinga•Sep 4, 2025, 11:13 AM
B of A Securities Maintains Buy on 89bio, Lowers Price Target to $29
📈 PositiveBenzinga•Aug 25, 2025, 04:49 PM
Frequently Asked Questions about ETNB
What is ETNB's current stock price?
89bio, Inc. (ETNB) is currently trading at $14.84 per share. The stock has moved +0.00% today.
What is the analyst price target for ETNB?
The average analyst price target for ETNB is $14.50, based on 1 analyst.
What sector is 89bio, Inc. in?
89bio, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ETNB's market cap?
89bio, Inc. has a market capitalization of $2.20 billion, making it a mid-cap company.
Does ETNB pay dividends?
No, 89bio, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAGIO
Agios Pharmaceuticals, Inc.
$24.46
Mkt Cap: $1.4B
BEAM
Beam Therapeutics Inc.
$26.57
Mkt Cap: $2.7B
COGT
Cogent Biosciences, Inc.
$39.55
Mkt Cap: $5.6B
DNLI
Denali Therapeutics Inc.
$16.85
Mkt Cap: $2.5B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
IBRX
ImmunityBio, Inc.
$2.08
Mkt Cap: $2.0B
LQDA
Liquidia Corporation
$34.53
Mkt Cap: $3.0B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
RCUS
Arcus Biosciences, Inc.
$21.98
Mkt Cap: $2.4B
RXRX
Recursion Pharmaceuticals, Inc.
$4.26
Mkt Cap: $1.7B
Explore stocks similar to ETNB for comparison